Grail

Grail developed Galleri, a multi-cancer early detection test that screens for over 50 types of cancer through a single blood draw. The company was spun out of Illumina and later reacquired amid regulatory challenges. Grail's technology could transform cancer screening from organ-specific tests to comprehensive blood-based surveillance.